Shares of Bradmer Pharmaceuticals Inc. (TSE:GLX – Get Free Report) have been given a consensus recommendation of “Buy” by the six ratings firms that are covering the company, MarketBeat reports. Two research analysts have rated the stock with a hold rating, one has issued a buy rating and three have issued a strong buy rating on the company.
Separately, Chardan Capital raised Bradmer Pharmaceuticals to a “strong-buy” rating in a research note on Monday, May 4th.
Get Our Latest Stock Analysis on GLX
Bradmer Pharmaceuticals Price Performance
Featured Stories
- Five stocks we like better than Bradmer Pharmaceuticals
- Why SK hynix Could Be the Best AI Chip Stock to Buy Now
- Seagate Technology Stock Surges as Earnings Beat Silences AI Doubters
- Alphabet Is Down 18% From Its High After a Stellar Quarter—Overdone, or More Downside Ahead?
- Why Bloom Energy May Be the Most Important AI Infrastructure Stock
Receive News & Ratings for Bradmer Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bradmer Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
